Report No. 28/2026 Receipt of the EMA List of Questions in the Process of Seeking a Positive Recommendation for the Marketing Authorisation of the Veterinary Medicinal Product BCX-CM-J

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”), with reference to ESPI Current Report No. 24/2026 dated 15 July 2026, hereby informs that on 16 July 2026 the Company received from the European Medicines Agency (the “EMA”) a list of questions regarding BCX-CM-J, a […]

Report No. 27/2026 Resolutions adopted by the Ordinary General Meeting of Shareholders on 16 July 2026.

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”) hereby publishes, as an attachment to this current report, the resolutions adopted by the Ordinary General Meeting of Shareholders (the “OGM”) held on 16 July 2026 following the adjournment announced on 23 June 2026 and subsequently […]

Report No. 26/2026 List of Shareholders Holding at Least 5% of the Total Number of Votes at the Ordinary General Meeting of Shareholders Following the Resumption of the Meeting on 16 July 2026

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”) hereby publishes the list of shareholders who, at the Ordinary General Meeting of Shareholders of the Issuer (the “OGM”) held on 16 July 2026 and continued following adjournments announced on 23 June 2026 and 7 July […]